Table 1.
Table illustrating patient characteristics.
| Patient characteristics | All patients (n = 35) |
|---|---|
| Age | |
| Median age | 47 years |
| Range | 19–76 years |
| Gender: male | 24 (69%) |
| Patients with ongoing corticosteroid therapy | 9 (26%) |
| ECOG performance status (0 to 1) | 29 (83%) |
| Pretreatment status (number of prior regimens)a | |
| 2 | 8 (23%) |
| 3 | 19 (54%) |
| More than 3 | 8 (23%) |
| Pretreatment status (number of prior agents used)b | |
| 3 | 15 (43%) |
| More than 3 | 12 (34%) |
| IDH status | |
| Unmutated | 16 (46%) |
| Mutated | 10 (29%) |
| Unknown | 9 (25%) |
aAll patients had progressed on at least one prior bevacizumab regimen, with 8 (23%) having progressed on two prior bevacizumab regimens. The median time to progression on prior bevacizumab therapy before study entry was 105 days.
bAll patients had at least 3 prior agents used before enrollment in the trial.